Aligos Therapeutics, Inc.
ALGS
NASDAQ·Healthcare·Biotechnology·Mkt cap $42.8M
$6.91
▼ -2.26%
P/E
—
Mkt Cap
$42.8M
52-Wk Range
$3.98–$13.69
52-Week Range
$3.98 - $13.69
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 34.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary oligonucleotide polymer and capsid assembly modulator technologies
- Strategic partnerships with Merck, Emory University, and other leading research institutions
- Diversified pipeline addressing multiple viral and metabolic disease indications
- Clinical-stage advantages with multiple candidates in active trials
Bear Case
1 risk
- High volatility (beta 2.3). Larger-than-normal price swings expected.
Growth
Moderate growth ahead
Advancement of ALG-010133 and ALG-000184 through Phase Ib/Phase I clinical trials for CHB
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+21.2% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ALGS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.14 vs -$1.09 consensus (+87.2% surprise). Revenue of $27.8M vs $24.7M expected (+12.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+87.2%
Revenue trend · last 8Q
—
—
-68%
-9%
-42%
-73%
+810%
+2779%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.3M
$629.0K
$311.0K
$965.0K
$741.0K
$169.0K
$2.8M
$27.8M
Margins · last 8Q
Gross
100.0%
Operating
-6.8%
Profit
-5.4%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 10, 2026
vs Industry
How ALGS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related